The Latest Cardiac and Vascular News
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient […]
Further analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, explores the effect of KERENDIA® (finerenone) on cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease associated with type 2 diabetes, with and without history of CV […]
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke. Asundexian is […]
Market availability of the cardiovascular disease prevention module co-developed with Bayer demonstrates One Drop’s continued expansion into new therapeutic areas NEW YORK, Oct. 27, 2021 /PRNewswire/ — One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, […]
Seven U.S. researchers working to advance pulmonary hypertension (PH) science and patient care awarded a combined one million dollars in grants Application for the 2021 PHAB Awards is now live for eligible researchers to submit their proposals WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer […]
FIGARO-DKD is the first contemporary cardiorenal outcomes trial with the majority of patients who had an eGFR ≥60 ml/min/1.73m2 to show cardiovascular benefit in chronic kidney disease associated with type 2 diabetes; patients were included in this study if they had […]
The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat […]
Bayer and Blackford Analysis have entered into a development and license agreement to establish an artificial intelligence (AI) platform for medical imaging. This agreement supports Bayer’s commitment to expanding its AI capabilities and accelerating innovation in radiology INDIANOLA, Pa.–(BUSINESS WIRE)–During […]
Late-breaking data presented at AHA 2020 Scientific Sessions and published simultaneously in Circulation WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, […]
New 220,000 square-foot Distribution Center to support ongoing growth of business PITTSBURGH–(BUSINESS WIRE)–Bayer announced its plans to build a new 220,000 sq. ft. Distribution Center to support the ongoing growth of Bayer’s Radiology global business that supplies medical device products […]
